Variables | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
5-year LRR % (events) | P | HR (95%CI) | P | 5-year OS % (events) | P | HR (95%CI) | P | 5-year DFS % (events) | P | HR (95%CI) | P | |
Treatment center | ||||||||||||
Cohort 1 | 6.1 (152) | 1.00 | 93.9 (148) | 1.00 | 85.5 (367) | 1.00 | ||||||
Cohort 2 | 7.5 (97) | .229 | 0.94 (0.73–1.23) | .675 | 91.6 (105) | .012 | 1.08 (0.86–1.37) | .491 | 83.5 (216) | .672 | 0.87 (0.73–1.04) | .122 |
Year | ||||||||||||
1999–2008 | 7.6 (142) | 1.00 | 91.5 (158) | 1.00 | 82.8 (328) | 1.00 | ||||||
2009–2014 | 5.6 (107) | .033 | 1.00 (0.76–1.33) | .980 | 94.9 (95) | < .001 | 0.79 (0.61–1.03) | .079 | 86.7 (255) | < .001 | 0.88 (0.74–1.06) | .187 |
Age (years) | ||||||||||||
≤ 40 | 9.6 (65) | 1.00 | 92.6 (52) | 1.00 | 81.0 (134) | 1.00 | ||||||
> 40 | 5.9 (184) | .002 | 0.61 (0.48–1.80) | < .001 | 93.2 (201) | .184 | 0.77 (0.61–0.97) | .026 | 85.8 (449) | .013 | 0.74 (0.62–0.87) | < .001 |
T stage | ||||||||||||
T1 | 3.9 (70) | 1.00 | 94.9 (87) | 1.00 | 89.6 (188) | 1.00 | ||||||
T2 | 9.1 (179) | < .001 | 1.87 (1.47–2.38) | < .001 | 91.4 (166) | < .001 | 1.58 (1.28–1.93) | < .001 | 80.6 (396) | < .001 | 1.58 (1.36–1.83) | < .001 |
SLNB | ||||||||||||
No | 7.6 (240) | 1.00 | 92.9 (250) | 1.00 | 84.7 (568) | 1.00 | ||||||
Yes | 6.2 (9) | .635 | 2.24 (1.23–4.09) | .008 | 98.1 (3) | .046 | 0.83 (0.36–1.92) | .670 | 90.1 (15) | .103 | 1.11 (0.69–1.80) | .659 |
No. of ALND | ||||||||||||
≤ 19 | 7.2 (73) | 1.00 | 92.3 (183) | 1.00 | 83.4 (411) | 1.00 | ||||||
> 19 | 5.5 (76) | .200 | 0.85 (0.66–1.08) | .186 | 94.6 (70) | .012 | 0.78 (0.63–0.97) | .029 | 87.7 (171) | .008 | 0.82 (0.70–0.96) | .013 |
No. of positive nodes | ||||||||||||
1 | 5.8 (112) | 1.00 | 94.0 (115) | 1.00 | 85.8 (281) | 1.00 | ||||||
2 | 7.1 (80) | 1.53 (1.19–1.97) | .001 | 92.9 (77) | 1.21 (0.97–1.51) | .084 | 84.5 (179) | 1.18 (1.01–1.39) | .041 | |||
3 | 8.0 (57) | .002 | 1.77 (1.33–2.36) | < .001 | 90.8 (61) | .049 | 1.43 (1.12–1.84) | .004 | 82.9 (123) | .006 | 1.32 (1.09–1.58) | .004 |
Lymphovascular invasion | ||||||||||||
No | 6.1 (189) | 1.00 | 93.5 (195) | 1.00 | 85.8 (447) | 1.00 | ||||||
Yes | 8,7 (37) | 1.27 (0.92–1.75) | .146 | 91.5 (32) | 1.03 (0.75–1.42) | .851 | 80.7 (82) | 1.16 (0.93–1.44) | .196 | |||
Unknown | 8.5 (23) | .053 | 0.76 (0.48–1.21) | .254 | 90.4 (26) | .100 | 0.92 (0.64–1.33) | .655 | 80.3 (54) | .056 | 0.92 (0.69–1.24) | .590 |
Histological grade | ||||||||||||
I- II | 4.8 (103) | 1.00 | 94.6 (110) | 1.00 | 87.8 (266) | 1.00 | ||||||
III | 10.3 (83) | 1.41 (1.08–1.84) | .011 | 91.4 (76) | 1.35 (1.06–1.71) | .014 | 81.6 (172) | 1.20 (1.01–1.43) | .042 | |||
Unknown | 8.6 (63) | < .001 | 1.21 (0.87–1.69) | .259 | 90.7 (67) | < .001 | 1.03 (0.77–1.37) | .851 | 80.5 (145) | < .001 | 1.10 (0.89–1.35) | .389 |
Surgery type | ||||||||||||
MRM | 7.0 (240) | 1.00 | 92.7 (241) | 1.00 | 84.0 (557) | 1.00 | ||||||
BCS | 2.3 (9) | .001 | 1.00 (0.54–1.86) | .996 | 96.5 (12) | .001 | 1.19 (0.72–1.99) | .495 | 92.9 (27) | < .001 | 0.79 (0.55–1.14) | .204 |
Radiotherapy | ||||||||||||
No | 7.6 (209) | 1.00 | 92.5 (202) | 1.00 | 84.1 (445) | 1.00 | ||||||
Yes | 3.8 (40) | < .001 | 0.42 (0.29–0.59) | < .001 | 94.7 (51) | < .001 | 0.62 (0.46–0.83) | .001 | 86.8 (138) | .001 | 0.77 (0.64–0.94) | .009 |
Chemotherapy | ||||||||||||
No | 4.7 (10) | 1.00 | 89.1 (23) | 1.00 | 83.9 (35) | 1.00 | ||||||
Yes | 6.7 (239) | 0.96 (0.44–2.09) | .922 | 93.3 (229) | 0.40 (0.22–0.71) | .002 | 84.9 (546) | 0.52 (0.33–0.80) | .003 | |||
Unknown | 0 (0) | .546 | 0.58 (0.07–4.55) | .606 | 94.4 (1) | < .001 | 0.23 (0.03–1.69) | .149 | 88.9 (2) | .003 | 0.28 (0.07–1.17) | .081 |
Chemotherapeutic drug | ||||||||||||
Taxane-based | 6.1 (142) | 1.00 | 94.5 (123) | 1.00 | 86.4 (324) | 1.00 | ||||||
Others | 8.6 (88) | 1.42 (1.08–1.87) | .011 | 90.6 (95) | 1.22 (0.96–1.56) | .103 | 80.7 (201) | 1.20 (1.01–1.44) | .041 | |||
Unknown | 4.5 (19) | .005 | 0.87 (0.48–1.57) | .614 | 91.4 (35) | < .001 | 1.11 (0.66–1.88) | .692 | 86.3 (58) | < .001 | 0.89 (0.61–1.30) | .551 |
Hormone receptor & Hormonal therapy | ||||||||||||
negative & no | 13.0 (106) | 1.00 | 85.9 (108) | 1.00 | 73.2 (223) | 1.00 | ||||||
positive & yes | 4.6 (118) | 0.52 (0.40–0.66) | < .001 | 95.6 (108) | 0.44 (0.35–0.55) | < .001 | 89.0 (286) | 0.55 (0.47–0.65) | < .001 | |||
positive & no | 6.5 (18) | 0.49 (0.30–0.78) | .003 | 90.5 (26) | 0.78 (0.56–1.09) | .153 | 81.7 (53) | 0.67 (0.50–0.89) | .005 | |||
Unknown | 6.1 () | < .001 | 0.79 (0.43–1.47) | .465 | 90.9 (11) | < .001 | 0.59 (0.34–1.02) | .060 | 82.4 (21) | < .001 | 0.74 (0.50–1.11) | .144 |
HER2 & Target therapy | ||||||||||||
negative & no | 5.7 (145) | 1.00 | 94.1 (147) | 1.00 | 86.5 (352) | 1.00 | ||||||
positive & yes | 4.9 (10) | 0.84 (0.46–1.53) | .578 | 98.6 (3) | 0.44 (0.20–0.93) | .032 | 90.2 (19) | 0.63 (0.41–0.98) | .038 | |||
positive & no | 12.0 (63) | 1.55 (1.18–2.04) | .002 | 87.7 (62) | 1.35 (1.05–1.73) | .017 | 75.7 (133) | 1.33 (1.10–1.60) | .003 | |||
Unknown | 6.1 (31) | < .001 | 1.07 (0.77–1.50) | .677 | 91.4 (41) | < .001 | 1.13 (0.86–1.49) | .374 | 84.3 (79) | < .001 | 1.03 (0.83–1.27) | .788 |